GAMMA Investing LLC Has $178,000 Stock Holdings in Alkermes plc (NASDAQ:ALKS)

GAMMA Investing LLC increased its position in shares of Alkermes plc (NASDAQ:ALKS) by 31.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,396 shares of the company’s stock after acquiring an additional 1,305 shares during the period. GAMMA Investing LLC’s holdings in Alkermes were worth $178,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Pallas Capital Advisors LLC purchased a new position in Alkermes in the first quarter valued at about $204,000. Wedge Capital Management L L P NC raised its stake in shares of Alkermes by 5.0% during the 1st quarter. Wedge Capital Management L L P NC now owns 117,516 shares of the company’s stock worth $3,880,000 after purchasing an additional 5,607 shares in the last quarter. Private Client Services LLC acquired a new stake in shares of Alkermes during the 1st quarter valued at about $929,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Alkermes by 60.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,107 shares of the company’s stock valued at $463,000 after buying an additional 6,073 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Alkermes in the 4th quarter valued at approximately $3,273,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analysts Set New Price Targets

ALKS has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Alkermes from $40.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Wall Street Zen lowered shares of Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 5th. HC Wainwright reaffirmed a “neutral” rating on shares of Alkermes in a research note on Friday, May 2nd. Royal Bank Of Canada upped their target price on Alkermes from $39.00 to $40.00 and gave the stock a “sector perform” rating in a research report on Friday, May 2nd. Finally, Robert W. Baird raised their price target on Alkermes from $38.00 to $41.00 and gave the company an “outperform” rating in a research report on Friday, May 2nd. Three research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Insider Buying and Selling

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total transaction of $103,654.06. Following the sale, the senior vice president owned 86,208 shares in the company, valued at $2,680,206.72. The trade was a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.40% of the stock is currently owned by company insiders.

Alkermes Stock Down 0.9%

ALKS stock opened at $28.75 on Friday. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The company has a market cap of $4.74 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44. The business’s 50-day simple moving average is $30.12 and its 200 day simple moving average is $30.89.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. Alkermes had a return on equity of 27.52% and a net margin of 23.30%. Alkermes’s revenue was down 12.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 EPS. On average, equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.